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Facioscapulohumeral muscular dystrophy (FSHD) is caused by
epigenetic de-repression of the disease locus, leading to patho-
genic misexpression of the DUX4 gene in skeletal muscle.
While the factors and pathways involved in normal repression
of the FSHD locus in healthy cells have been well characterized,
very little is known about those responsible for the aberrant
activation of DUX4-ﬂ in FSHD myocytes. Reasoning that
DUX4-ﬂ activators might represent useful targets for small
molecule inhibition, we performed a highly targeted, candi-
date-based screen of epigenetic regulators in primary FSHD
myocytes. We conﬁrmed several of the strongest and most spe-
ciﬁc candidates (ASH1L, BRD2, KDM4C, and SMARCA5) in
skeletal myocytes from two other unrelated FSHD1 patients,
and we showed that knockdown led to reduced levels of
DUX4-ﬂ and DUX4-FL target genes, as well as altered chro-
matin at the D4Z4 locus. As a second mode of validation, tar-
geting the CRISPR/dCas9-KRAB transcriptional repressor to
the promoters of several candidates also led to reduced levels
of DUX4-ﬂ. Furthermore, these candidates can be repressed
by different methods in skeletal myocytes without major effects
on certain critical muscle genes. Our results demonstrate that
expression ofDUX4-ﬂ is regulated by multiple epigenetic path-
ways, and they indicate viable, druggable candidates for thera-
peutic target development.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is the third most
common muscular dystrophy,1,2 characterized by progressive weak-
ness and atrophy of speciﬁc muscle groups. FSHD is also marked
by a high variability in disease onset, progression, and severity, which
ranges from asymptomatic to clinically severe.1,3–5 This high vari-
ability within the clinical spectrum suggests the involvement of mul-
tiple factors, including epigenetic regulators. Indeed, both forms of
the disease are linked by epigenetic dysregulation of the D4Z4 macro-
satellite repeat array at chromosome 4q35. FSHD1, the most common
form of the disease, is linked to contractions at this array,6–8 resulting
in relaxation of chromatin that is normally repressed. FSHD2 is
contraction independent, but mutations in proteins that maintain
epigenetic silencing lead to a similar relaxation of chromatin in the
region.9,10 One critical consequence of this epigenetic alteration is
the aberrant expression of the DUX4 retrogene in skeletal muscle.
While DUX4 resides in every D4Z4 repeat unit in the macrosatellite
array, only the full-length DUX4 mRNA (DUX4-ﬂ) encoded by the
distal-most repeat is stably expressed, due to the presence of a poly-
adenylation signal in disease-permissive alleles.11,12 The DUX4-FL
protein acts as a transcription factor and is highly cytotoxic when
overexpressed. Endogenous DUX4-FL activates germline genes,
immune mediators, and retroelements,13,14 alters RNA and protein
metabolism,15,16 and leads to accumulated muscle pathology.
As with many repetitive elements in the human genome, the D4Z4
macrosatellite array that encodes DUX4 is normally under strong
epigenetic repression in adult somatic cells (reviewed in Himeda
et al.17). FSHD patients exhibit a loss of this repression, displaying
chromatin relaxation (reduced enrichment of the repressive
H3K9me3 mark, HP1g, and cohesin) at D4Z4 arrays18,19 and DNA
hypomethylation at the 4q D4Z4 array.20–25 Thus, targeting the epige-
netic dysregulation in FSHD is a viable potential therapeutic
avenue.17 In support of this approach, a forward genetic screen to
identify regulators of repeat-induced variegation of expression in
transgenic mice carrying a metastable repeat epiallele identiﬁed
numerous chromatin-modifying factors, classiﬁed as the Momme
(Modiﬁer ofMurineMetastable Epiallele) genes, involved in either re-
pressing or enhancing the variegated gene expression phenotype.26–28
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Importantly, mice carrying mutations in genes encoding enhancers
of gene expression from large DNA repeat arrays were otherwise
healthy, suggesting that the levels of certain factors functioning in
the regulation of large repeat arrays can be decreased without global
epigenetic dysregulation.
Correction of the epigenetic defect in FSHD has been attempted in
proof-of-principle studies by our lab and others, using the dCas9-
KRAB transcriptional inhibitor29 and the DICER/Argonaute sys-
tem.30 Here we took a different approach, screening a pre-selected
panel of epigenetic regulators, including the human orthologs of
several Momme genes, and chromatin-modifying enzymes for their
role in maintaining DUX4-ﬂ mRNA expression in primary human
FSHD myocytes. Since we are keenly interested in identifying targets
for developing small molecule inhibitors and therapeutics for FSHD,
it was vital that our selected targets have a high potential for selective
druggability. Using a combination of techniques for validation, we
have uncovered several epigenetic regulators as promising targets
for FSHD therapeutic development.
RESULTS
Multiple Epigenetic Pathways Regulate the Expression of
DUX4-fl in FSHD Myocytes
Utilizing our understanding of the epigenetics impacting the FSHD re-
gion and theMomme enhancer genes,17 we hypothesized thatmultiple
epigenetic and chromatin-regulatory pathways might be deregulated
in FSHD myocytes, with many potential targets for therapeutic
manipulation. Since the pathogenic expression ofDUX4-ﬂ is restricted
to differentiated human skeletal muscle, where it is expressed sporad-
ically at very low levels, regulators of DUX4-ﬂ expression are not
readily amenable to high-throughput screening. Thus, we designed a
highly focused, candidate-based screen in a larger format using pri-
mary FSHD myocytes. We pre-selected 36 candidate activators of
DUX4-ﬂ as potential drug targets based on likelihood of functioning
at the contracted D4Z4 macrosatellite, activity predicting a role in
transcriptional activation, or establishing or maintaining a euchro-
matic environment, and the presence of druggable protein domains
(Table 1). Although very little is known about mechanisms of activa-
tion at D4Z4, mechanisms of repression have been well characterized.
Thus, we reasoned that epigenetic regulators opposing D4Z4-repres-
sive factors and histone marks would be good candidates for our
small-scale, biased screen. These candidates include transcriptional
regulators, chromatin remodelers, and histone-modifying enzymes.
For our initial screen, we used primary skeletal myocytes from an
FSHD1 patient (05Abic) that express consistent and relatively high
levels of DUX4-ﬂ when terminally differentiated.31 Using lentivirus-
encoded small hairpin RNAs (shRNAs), we knocked down each
candidate in terminally differentiated cultures, then harvested the
cells 4 days later, and assessed the expression of DUX4-ﬂ and other
genes, including key muscle factors. The lack of a major effect on
muscle genes is critically important from the perspective of ultimately
developing and administering a chronic therapeutic agent. However,
this also represents a potential problem with gene knockdown strate-
gies targeting ubiquitous transcriptional activators or with non-spe-
ciﬁc epigenetic drugs. Somatic DUX4-ﬂ expression is predominantly
restricted to differentiated skeletal muscle, due to regulation by two
myogenic enhancers that activate DUX4-ﬂ in an epigenetically
permissive environment.32 Therefore, any manipulation that indi-
rectly decreases DUX4-ﬂ expression by affecting myogenic differenti-
ation or the levels of key muscle factors is not a viable therapeutic
avenue for FSHD. Thus, the minimal key criteria for viable therapeu-
tic targets emerging from our screen are those regulators whose
knockdown results in a reduction of DUX4-ﬂ levels without affecting
the expression of critical muscle genes.
Interestingly, the results of our targeted knockdown screen revealed
that many of these candidates do, in fact, appear to play a role in regu-
lating DUX4-ﬂ expression as predicted (Table S1). For example,
ASH1L, the mammalian homolog of the Drosophila Trithorax group
protein that counteracts Polycomb-mediated gene silencing, is a his-
tone methyltransferase that has been reported to activate DUX4-ﬂ
expression in FSHD.33–36 ASH1L is thought to be recruited proximal
to the D4Z4 array by the DBE-T long noncoding RNA (lncRNA),
resulting in H3K36me2 enrichment and de-repression of the FSHD
locus.36 Strikingly, we found that knockdown of ASH1L with three
different shRNAs reduced DUX4-ﬂ expression by 70%–80% (Fig-
ure 1A). Likewise, knockdown of the epigenetic reader BRD2, the
lysine-speciﬁc histone demethylase KDM4C, and the chromatin-re-
modeling factors BAZ1A and SMARCA5 substantially reduced levels
of DUX4-ﬂ (Figures 1B–1E). Importantly, these knockdowns had
minimal effects on expression of the key muscle transcription factors
MYOD1 and MYOG (Figure 1), indicating that DUX4-ﬂ repression
was not caused by reduced levels of myogenic regulatory factors.32
Levels of the muscle structural protein MYH1 and FRG1, an FSHD
candidate gene that lies proximal to the D4Z4 array, were also rela-
tively unchanged (Figure 1). Depletion of BRD2 in HeLa cells has
been reported to cause widespread changes in gene expression,
including a decrease in UTRN levels;37 we observed a similar slight
decrease in expression of UTRN following BRD2 knockdown in
FSHDmyocytes (Figure 1C). We also conﬁrmed that the knockdown
of our top candidates does not affect the ability of myoblasts to fuse
and form multinucleated myotubes (Figure S1). Thus, although a
global analysis of changes in gene expression is beyond the scope of
this study, these results suggest that certain epigenetic pathways con-
trolling DUX4-ﬂ expression in FSHD can be modulated without
major adverse effects on muscle differentiation.
To conﬁrm our top candidates across FSHD patient cohorts, we tested
shRNA knockdowns of ASH1L, BRD2, KDM4C, and SMARCA5 in
myocytes from two other unrelated FSHD1 patients (18Abic and
17Abic), with similar results (Table S2). Although knockdown of
these candidates was incomplete (40%–60% reduction in mRNA
expression), at least one shRNA for each target reduced levels of
DUX4-ﬂ mRNA signiﬁcantly in myocytes from all three patient co-
horts (Figure 2; Table S3; Figure S2). As DUX4-FL protein levels
are low and difﬁcult to assess in FSHD myocytes, we chose to assess
DUX4-FL target gene expression as the more reliable assay and
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relevant functional readout of DUX4 activity. Importantly, DUX4-FL
targets thought to have pathogenic consequences13 are signiﬁcantly
decreased by knockdown of all four candidates in myocytes from
all three FSHD patients (Figure 2; Table S3; Figure S2). Thus,
reducing individual levels of these four FSHD therapeutic targets
signiﬁcantly decreases expression of DUX4-ﬂ and its downstream tar-
gets without altering the expression of certain key myogenic genes.
Transcriptional Repression of Epigenetic Regulators by dCas9-
KRAB Reduces DUX4-fl Expression in FSHD Myocytes
In our initial screen, knockdown of eight candidates by at least two
shRNAs resulted in >70% reduction ofDUX4-ﬂ expression, with min-
imal effects on other tested genes (Table S1). Based on the potential
for selective druggability, we selected ﬁve of these candidates,
ASH1L, BAZ1A, BRD2, KDM4C, and SMARCA5, for veriﬁcation by
Table 1. Candidate Epigenetic Regulators of DUX4-fl
Gene Alias Full Name Function
ASH1L – absent, small, or homeotic-like H3K4me3, H3K36me2/3 methyltransferase
BAP1 – BRCA1-Associated Protein 1 histone deubiquitinase; tumor suppressor
BAZ1A ACF1 Bromodomain Adjacent to Zinc-Finger Domain 1A ATP-dependent chromatin remodeler
BAZ1B WSTF Bromodomain Adjacent to Zinc-Finger Domain 1B ATP-dependent chromatin remodeler
BAZ2A TIP5 Bromodomain Adjacent to Zinc-Finger Domain 2A NoRC chromatin-remodeling complex
BPTF NURF301 Bromodomain PHD Finger Transcription Factor NURF chromatin-remodeling complex
BRD2 – Bromodomain containing 2 epigenetic reader
BRD3 – Bromodomain containing 3 epigenetic reader
BRD4 – Bromodomain containing 4 epigenetic reader
BRDT BRD6 Bromodomain testis associated epigenetic reader
BRPF1 – Bromodomain and PHD Finger Containing 1 epigenetic reader; MOZ HAT complex
BRPF3 – Bromodomain and PHD Finger Containing 3 epigenetic reader; HBO1 HAT complex
CARM1 PRMT4 Coactivator Assoc. Arginine Methyltransferase 1 H3R17 methyltransferase
KDM4A JMJD2A Lysine (K)-speciﬁc demethylase 4A H3K9me3 & H3K36me3 demethylase
KDM4B JMJD2B Lysine (K)-speciﬁc demethylase 4B H3K9me3 & H3K36me3 demethylase
KDM4C JMJD2C Lysine (K)-speciﬁc demethylase 4C H3K9me3 & H3K36me3 demethylase
KDM4D JMJD2D Lysine (K)-speciﬁc demethylase 4D H3K9me2/3 demethylase
KDM6A UTX Lysine (K)-speciﬁc demethylase 6A H3K27me2/3 demethylase
KDM6B JMJD3 Lysine (K)-speciﬁc demethylase 6B H3K27me2/3 demethylase
KMT2A MLL Lysine (K)-speciﬁc methyltransferase 2A H3K4me1/2 methyltransferase
KMT2C MLL3 Lysine (K)-speciﬁc methyltransferase 2C H3K4me1 methyltransferase
KMT2E MLL5 Lysine (K)-speciﬁc methyltransferase 2E (no methyltransferase activity)
MYSM1 – Myb-like, SWIRM, and MPN Domains 1 histone (H2A) deubiquitinase
NEK6 – NIMA-Related Kinase 6 histone (H1, H3) kinase
PHF2 CENP-35 PHD-Finger Protein 2 H3K9me2 demethylase
PRMT1 – Protein Arginine Methyltransferase 1 H4R3 methyltransferase
SETD1A KMT2F SET Domain Containing 1A H3K4 methyltransferase
SETD1B KMT2G SET Domain Containing 1B H3K4 methyltransferase
SF3B1 SAP155 Splicing Factor 3b Subunit 1 spliceosome component; B-WICH complex
SMARCA5 SNF2H
SWI/SNF-Related, Matrix-Associated, Actin-Dependent
Regulator of Chromatin, Subfamily A, Member 5
NoRC, B-WICH, NURF, ACF1, RSF, chromatin-remodeling
complexes
SMARCB1 SNF5 and BAF47
SWI/SNF-Related, Matrix-Associated, Actin-Dependent
Regulator of Chromatin, Subfamily B, Member 1
ATP-dependent chromatin remodeling
SMYD3 KMT3E SET and MYND Domain Containing 3 H3K4 methyltransferase
UFL1 – UFM1-Speciﬁc Ligase 1 E3 ligase
USP3 UBP Ubiquitin-Speciﬁc Peptidase 3 histone (H2A, H2B, and H2AX) deubiquitinase
USP7 TEF1 Ubiquitin-Speciﬁc Peptidase 7 histone (H2A, H2B) and non-histone deubiquitinase
USP16 UBPM Ubiquitin-Speciﬁc Peptidase 16 histone (H2A) deubiquitinase
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an independent method. Guided by appropriate single-guide RNA(s)
(sgRNA[s]), the enzymatically inactive dCas9 fused to transcriptional
effectors (KRAB, LSD1, VP64, and p300) can modulate endogenous
target gene expression inmammalian cells.38–42When recruited to re-
gions near the transcription start site (TSS) of active genes (50
to +250), dCas9-KRAB can be an effective transcriptional repressor,43
and we have used it successfully to repress DUX4-ﬂ expression in
differentiated FSHD myocytes, which are not readily amenable to
Cas9 cutting and selection.29 Thus, for each candidate, we designed
6–8 sgRNAs targeting the promoter or exon 1, and we transduced
these with dCas9-KRAB into 17Abic FSHD myocytes using four se-
rial co-infections with centrifugation, as in our previous study.29 Cells
were harvested 72 hr later and assayed for changes in gene expression.
While none of the tested sgRNAs targeting ASH1L consistently
affected expression of this candidate gene, we identiﬁed one func-
tional sgRNA for BRD2 and two independently functional sgRNAs
for BAZ1A, KDM4C, and SMARCA5 (Table S4). It is difﬁcult to
achieve strong repression of many transcriptional regulators, and
although the levels of CRISPR inhibition achieved with these inde-
pendent sgRNAs were modest (20%–60%), the results were
similar to those reported by other labs.39,43 However, as with the
shRNA knockdowns, even a small reduction of target gene expres-
sion proved sufﬁcient to signiﬁcantly reduce levels of DUX4-ﬂ
(by 40%–60%) (Figure 3; Figure S3; Table S5), which is ideal
from a therapeutic perspective. By contrast, the expression levels
of other genes (MYOD1, MYOG, MYH1, FRG1, and 18S) were
Figure 1. Knockdown of Epigenetic Regulators Reduces Expression of DUX4-fl in FSHD Myocytes
(A–E) Differentiated FSHDmyocytes were infected in two serial rounds with lentivirus expressing shRNAs indicated in each of the panel keys specific to ASH1L (A),BAZ1A (B),
BRD2 (C), KDM4C (D), SMARCA5 (E), or a scrambled control. Cells were harvested 4 days later for expression analysis of the full-length DUX4 isoform (D4-fl), myogenin
(Myog), MyoD, myosin heavy chain 1 (MyHC), FRG1, utrophin (Utr), and 18S by qRT-PCR. In all panels, data are plotted as the mean + SD value of three technical replicates,
with relative mRNA expression for mock-infected cells set to 1. Refer to Table S1 for results of the full screen.
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relatively unaffected by reduction of the candidate regulator (Fig-
ure 3; Figure S3). Importantly, DUX4-ﬂ was the only tested gene
to be signiﬁcantly reduced by both methods of repression (shRNA
knockdown and CRISPR inhibition). For example, knockdown of
SMARCA5 with one shRNA (13214) resulted in a 30% decrease
in MYOD1 (Figure 1E), but this was not recapitulated by the other
shRNA (13213) or by either sgRNA in the CRISPR inhibition exper-
iment, and, thus, it likely represents an off-target effect.
Knockdown of Epigenetic Regulators Increases Chromatin
Repression at the D4Z4 Macrosatellite Array
Since knocking down any of several epigenetic regulators in FSHD
myocytes led to a substantial decrease in expression of DUX4-ﬂ, we
wanted to assess changes in chromatin at the pathogenic locus.
Although DUX4 is present in every D4Z4 repeat unit at both 4q
and 10q alleles, the chromatin at three of these alleles is already
in a compacted, heterochromatic state. Thus, any attempt to assess
repression at the contracted allele would be dampened by the pres-
ence of the other three alleles. To remove 10q alleles from
the analysis, we took advantage of a chromosome 4- versus
10-speciﬁc sequence polymorphism in the DUX4 exon 2 in our
primer design.
To assess detectable chromatin changes, we performed chromatin
immunoprecipitation (ChIP) for several histone modiﬁcations
following shRNA knockdown of ASH1L, BRD2, KDM4C, or
SMARCA5 in 17Abic FSHD myocytes. For these experiments, we
used shRNAs that gave strong, consistent knockdowns of each target
gene across all FSHD cohorts tested. We found that levels of the
repressive H3K9me3 mark were increased in BRD2 and KDM4C
knockdown cells at the chromosome 4DUX4 exon1/intron1 (Figure 4;
Figure S4). Knockdown of the H3K36 methyltransferase ASH1L led
to the expected decrease in levels of H3K36me3 at DUX4; conversely,
knockdown of the H3K9/H3K36 demethylase KDM4C led to the
expected increase in both marks at DUX4 (Figure 4; Figure S4).
Although changes in enrichment were slight (45%–85%), these dif-
ferences were signiﬁcant (Table S6) and likely to be an underestimate,
as they reﬂect an increase in repression at the distal de-repressed
pathogenic repeat among a background of heterochromatic 4q re-
peats. With regard to this, patient 17A has5 repeat units on the con-
tracted 4A161 allele and 26 repeat units on the non-contracted 4A-
L161 allele. In all cases, there was no signiﬁcant change in levels of
enrichment at the heterochromatic 4p macrosatellite array, indicating
that these epigenetic modiﬁers are not acting broadly at repeat regions
across the genome.
Figure 2. Knockdown of Epigenetic Regulators Reduces DUX4-fl and DUX4-FL Target Gene Expression across Multiple FSHD Cohorts
(A–D) Differentiated myocytes from three unrelated FSHD patients (05Abic, 17Abic, and 18Abic) were infected in two serial rounds with shRNAs to ASH1L (16169) (A), BRD2
(6308) (B), KDM4C (22058) (C), SMARCA5 (13214) (D), or a scrambled control. Cells were harvested 4 days later for expression analysis of shRNA target genes;DUX4-fl; and
DUX4-FL target genes TRIM43, ZSCAN4, andMBD3L2 by qRT-PCR. In all panels, data are plotted as the mean + SD value of three independent experiments, with relative
mRNA expression for control-infected cells set to 1. *p < 0.05, **p < 0.01, and ***p < 0.001 are from comparing knockout to the corresponding control (n = 3 patients). Refer to
the Materials and Methods, Figure S2, and Tables S2 and S3 for additional details.
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As repressive histonemodiﬁcations can lead tomore stable repression
in the form of DNA methylation, we performed bisulﬁte sequencing
across the gene body of the distal pathogenicDUX4 repeat23 following
shRNA knockdown of ASH1L, BRD2, KDM4C, or SMARCA5 in
17Abic FSHD myocytes. While there were no changes in the pattern
of DNA hypomethylation seen across the main gene body of DUX4
(Figure S5A), we found that, by 4 days post-infection, there was a
small increase in DNA methylation at exon 3 in ASH1L, BRD2, and
SMARCA5 knockdown cells (Figure S5B). Although the functional
signiﬁcance of methylation at exon 3 is unclear, knockdown of these
epigenetic regulators serves to drive the methylation pattern at this re-
gion toward the higher levels seen in healthy myocytes (Figure S5B).
Since primary, terminally differentiated myocytes in culture are not
the ideal system in which to assess long-term changes, we expect
that any substantial increase in DNA methylation will require assess-
ment in a more physiologically relevant model.
In summary, using several different methods, we have demonstrated
that independent knockdown of multiple chromatin regulators re-
sults in chromatin repression at D4Z4 and a substantial decrease in
DUX4-ﬂ expression in FSHD myocytes. Our results provide proof
of principle that even modest inhibition of certain epigenetic path-
ways can substantially reduce levels of DUX4-ﬂ, demonstrating their
potential as novel drug targets for FSHD.
DISCUSSION
In a previous study, we successfully corrected the underlying defect in
FSHD by using dCas9-KRAB (CRISPR inhibition) to return the aber-
rantly relaxed chromatin at the disease locus to a more repressed
state.29 However, due to limitations in current technology and deliv-
ery, our CRISPR inhibition approach is many years away from being
clinically applicable. Small molecule therapeutics targeting the regu-
latory factors modulating DUX4-ﬂ expression at the FSHD locus
could overcome these limitations. Therefore, here we took a different
approach to this correction, identifying the potentially druggable
chromatin-regulatory pathways converging on the contracted
FSHD1 D4Z4 macrosatellite repeat, which represent therapeutic tar-
gets for designing inhibitory molecules. Using two complementary
modalities to knock down speciﬁc candidate regulators, we found
that many of these pathways serve to regulate DUX4-ﬂ expression
in FSHD myocytes. Importantly, while we have focused on only
several of these factors, the results from our initial screen indicate
that there are many viable potential candidates for FSHD drug devel-
opment, for any investigator who wishes to pursue them.
The identiﬁcation of multiple candidate regulators of DUX4-ﬂ is
perhaps not surprising, as many of these factors are part of the
same multi-protein complexes or function in the same regulatory
pathways (Table 2). For instance, SMARCA5 is a catalytic component
Figure 3. Transcriptional Repression of Epigenetic Regulators by dCas9-KRAB Reduces Expression of DUX4-fl in FSHD Myocytes
(A–D) Differentiated FSHD myocytes were subjected to four serial co-infections with combinations of lentiviral supernatants expressing either dCas9-KRAB or individual
sgRNAs (g1–2 for each target gene) targeting BAZ1A (A), BRD2 (B), KDM4C (C), or SMARCA5 (D). Cells were harvested72 hr later for analysis of gene expression by qRT-
PCR (as in Figure 1). Data are plotted as the mean + SD value of three independent experiments, with relative mRNA expression for cells infected with dCas9-KRAB alone set
to 1. *p < 0.05 and **p < 0.01 are from comparing sgRNAs to dCas9-KRAB alone. Refer to the Materials andMethods, Figure S3, and Tables S4 and S5 for additional details.
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of at least ﬁve chromatin-remodeling complexes (CHRAC, RSF, ACF/
WCRF, B-WICH, and NoRC44–48). SMARCA5 directly associates
with BAZ1A and BAZ2A, two other candidates from our screen, in
two distinct chromatin-remodeling complexes that enable DNA
replication through repressive chromatin and mediate heterochro-
matin formation at repetitive elements, respectively.49,50 SMARCA5
is also part of the B-WICH-remodeling complex—which includes
two other candidates from our screen, BAZ1B and the splicing factor
SF3B1—and part of the NURF complex with BPTF51 (Table 2). These
complex interaction networks, and the large families these factors
belong to, are largely responsible for the toxicity of current epigenetic
drugs. However, as with the Momme genetic screen,26 our results
demonstrate that the reduction of certain epigenetic regulators can
have relatively speciﬁc effects. While a global gene expression analysis
would likely ﬁnd other changes, it is clear that our candidates are not
global regulators and have some speciﬁcity for D4Z4 arrays. This
speciﬁcity is not without precedent, as many repressive epigenetic
factors are relatively speciﬁc for the chromosome 4q and 10q D4Z4
arrays.17 For example, the highly speciﬁc de novo DNA methyltrans-
ferase DNMT3B is localized at D4Z4 arrays,52,53 and SMCHD1, the
chromatin-remodeling protein responsible for FSHD2, has a very
restricted genomic distribution, including D4Z4 macrosatellites.10,54
The identiﬁcation of potential targets from screens such as ours
should facilitate the development of more speciﬁc small molecule
inhibitors. For example, consistent with our results, a recent report
indicates that BET bromodomain inhibition decreases DUX4 expres-
sion in FSHD myocytes.55 However, the results of our epigenetic
screen indicate that pan-BRD inhibition is not necessary or even
desirable as a treatment for FSHD. We found that BRD2 knockdown
represses DUX4-ﬂ levels without major effects on muscle genes,
whereas knockdown of BRD3 or BRD4 either led to substantial effects
on other genes or was less effective at decreasing DUX4-ﬂ. Thus, the
development of drugs targeting speciﬁc isoforms as well as speciﬁc
protein interactions should decrease adverse effects, leading to greater
safety and efﬁcacy. This is particularly important, since combination
therapies may ultimately prove to be themost effective means of treat-
ing FSHD.
These epigenetic regulators have wide-ranging roles (e.g., cell prolif-
eration, differentiation, DNA repair, and apoptosis); thus, it is
possible that they are affecting DUX4-ﬂ expression indirectly. How-
ever, they are most likely reducing DUX4-ﬂ expression by modifying
the chromatin state at the pathogenic locus. Even a modest reduction
in expression of these factors led to enhanced chromatin repression at
the chromosome 4q D4Z4 array, detectable even on a background of
heterochromatic repeats, and a striking decrease in DUX4-ﬂ expres-
sion. The ability to modulate levels of DUX4-ﬂ without completely
abolishing expression of its upstream regulators, all of which play
important and diverse cellular roles, is particularly encouraging for
the development of targeted therapies.Within FSHD families, asymp-
tomatic individuals still express detectable levels of DUX4-ﬂ (lower
than those of their manifesting siblings),24,31 suggesting that DUX4
expression doesn’t need to be completely silenced, merely reduced,
to see a therapeutic effect. The catastrophic effects of small increases
in DUX4-ﬂ levels in mouse models56,57 also suggest that even small
decreases in expression will be beneﬁcial to patients. While the estab-
lishment of stable, long-term repression will be important to demon-
strate, we found that knockdown of several regulators led to an
increase in DNA methylation at exon 3 of DUX4 as early as 4 days
post-infection. Unfortunately, primary FSHD myotubes—which are
not undergoing replication and are not amenable to gene editing, se-
lection, or long-term culturing—are not the best model in which to
test long-term epigenetic changes. Cells such as the newly reported
FSHD lymphoblast lines, which express DUX4-ﬂ mRNA and mimic
patterns of DNA methylation seen in FSHD myocytes,58 would be
Figure 4. Knockdown of Epigenetic Regulators Alters Chromatin at the D4Z4 Macrosatellite Array
(A and B) Differentiated FSHDmyocytes were infected in two serial rounds with shRNAs to ASH1L,BRD2,KDM4C,SMARCA5, an empty control, or a GFP control. Cells were
harvested 4 days later for ChIP analysis. Chromatin was immunoprecipitated using antibodies specific for H3K9me3 (A), H3K36me3 (B), or H3, and it was analyzed by qPCR
using primers specific to DUX4 exon1/intron1 on chromosome 4 (4q-spec DUX4) or the 4p macrosatellite array on chromosome 4. Data are presented as fold enrichment of
the target region by aH3K9me3 or aH3K36me3 normalized to a-histone H3, with enrichment for the empty control shRNA-infected cells set to 1. Data are plotted as the
mean +SD value of at least three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 are from comparing knockout to the corresponding empty control. Refer to
the Materials and Methods, Figure S4, and Table S6 for additional details.
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better suited for assessing DNA methylation changes in response to
the depletion of DUX4-ﬂ regulators. In response to epigenetic drugs,
these lymphoblasts show a similar induction ofDUX4-ﬂ expression to
that seen in FSHDmyocytes,58 suggesting that at least some upstream
regulatory pathways are maintained in non-muscle cells.
It is likely that multiple epigenetic pathways have evolved to repress
repetitive elements within the human genome. The DUX4 retrogene
appears to have a normal developmental role in the testis;12 however,
silencing ofDUX4 and the D4Z4macrosatellite repeat is critical in so-
matic tissues. Although DUX4-ﬂ is only rarely expressed in FSHD
myocytes at any given time, it is epigenetically poised for expression
in a majority of these cells,24,29 indicating a general deregulation of
repressive upstream mechanisms. Our results suggest that, in the
absence of normal repression, activating pathways are aberrantly
active and even modest perturbations in these pathways may be suf-
ﬁcient to reduce levels of DUX4-ﬂ.
How these regulators activate DUX4 in FSHD myocytes is an impor-
tant question that may bear on the normal function of DUX4 during
development. DUX4 is normally expressed in the testis, where epige-
netic mechanisms are critically important for regulating spermato-
genesis. The abnormal activation of testis genes is not unprecedented:
cancer/testis antigens—genes normally expressed in the male germ-
line that encode immunogenic proteins—are epigenetically activated
in many types of cancer. Interestingly, many DUX4-FL targets are
also cancer/testis antigens.13 Although the mechanisms controlling
DUX4 expression in germ cells are still uncharacterized, the upstream
enhancers driving DUX4 transcription in FSHDmyocytes contain el-
ements for both muscle and testis factors.32 Thus, it seems plausible
that, in the absence of normal somatic repression, epigenetic path-
ways that activate DUX4 in the testis could be aberrantly activated
in skeletal muscle, allowing muscle factors inappropriate access to
DUX4-regulatory regions. Further characterization of these mecha-
nisms should help to uncover additional targets for therapeutic
development.
MATERIALS AND METHODS
Plasmids and Antibodies
The pHAGE EF1-dCas9-KRAB (Addgene plasmid 50919) and
pLKO.1-puro U6 sgRNA BfuAI stuffer lentiviral plasmids were devel-
oped by ReneMaehr and ScotWolfe (Addgene plasmid 50920).40 The
ChIP-grade antibodies used in this study, a-H3K9me3 (ab8898),
a-H3K36me3 (ab9050), and a-histone H3 (ab1791), were purchased
from Abcam (Cambridge, MA).
sgRNA Design and Plasmid Construction
We used the publicly available sgRNA design tool from the Broad
Institute (http://www.broadinstitute.org/rnai/public/analysis-tools/
sgrna-design) to identify candidate sgRNAs targeting the promoter/
exon 1 regions of human BAZ1A, BRD2, KDM4C, and SMARCA5
(Supplemental Information; Table S4). To build in ﬂexibility for ex-
periments beyond the scope of this study, we prioritized sgRNAs
that target sequences ﬂanking dual protospacer adjacent motifs
(PAMs) recognizable by both SaCas9 and SpCas9. Predicted off-
target matches were determined using the CRISPR Design Tool
(http://crispr.mit.edu).59 6–8 sgRNAs for each target gene were
cloned individually into BfuAI sites in the pLKO.1-puro U6 sgRNA
BfuAI stuffer plasmid and sequence veriﬁed.
Cell Culture, Transient Transfections, and Lentiviral Infections
Myogenic cells were obtained from the Wellstone FSHD cell reposi-
tory housed at the University of Massachusetts Medical School,24,31
and normal human primary myoblasts were obtained from Lonza
(HSMM, lot 509793). Myogenic cultures derived from biceps muscles
of unrelated FSHD1 patients (05Abic, 17Abic, and 18Abic), normal
myoblasts, and 293T packaging cells were grown as described.29 Len-
tiviral particles expressing shRNAs were generated using The RNAi
Consortium (TRC) shRNA expression plasmids as previously
described,60 and they were obtained through the University of Massa-
chusetts Medical School RNAi Core Facility. FSHD1 skeletal myo-
blasts were grown to conﬂuence, and then allowed to self-differentiate
in growth medium for 48 hr. Cells were subjected to 2 rounds of
infection and harvested 4 days later (for shRNA knockdowns and
ChIP) or 4 rounds of infection and harvested 3 days later (for CRISPR
inhibition experiments), as described.29 For the assessment of fusion
index, normal primary myoblasts were switched to differentiation
conditions24,31 following shRNA knockdown.
qRT-PCR
Total RNAs were extracted using TRIzol (Invitrogen) and puriﬁed
using the RNeasy Mini kit (QIAGEN) after on-column DNase I
Table 2. Top Therapeutic Candidates for Targeted Repression of DUX4-fl
Candidate Target Domains Function and Complexes Candidate Interactions
ASH1L SET,63 Bromo,64 BAH,65 and PHD66 H3K36me2/3 methyltransferase –
BAZ1A/ACF1 Bromo,64 PHD,66 and WAC67
non-catalytic component that enhances and
directs function of SMARCA5 in the CHRAC-
and ACF-remodeling complexes
SMARCA5
BRD2 Bromo1 and Bromo264 binds hyperacetylated chromatin; regulates transcription –
KDM4C/JMJD2C jmjN/jmjC68 and PHD66 H3K9me3 and H3K36me3 demethylase PRMT1
SMARCA5/SNF2H
Helicase ATP-binding, Helicase C,69
SANT1, and SANT270
catalytic subunit of ATP-dependent chromatin-remodeling
complexes (CHRAC, RSF, ACF, B-WICH, NoRC, and NURF)
BAZ1A, BAZ1B, BAZ2A, SF3B1,
and BPTF
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digestion. Total RNA (2 mg) was used for cDNA synthesis using Su-
perscript III Reverse Transcriptase (Invitrogen), and 200 ng cDNA
was used for qPCR analysis as described.24 Oligonucleotide primer
sequences are provided in Table S7.
ChIP
ChIP assays were performed with lentiviral-infected 17Abic differen-
tiated myocytes using the Fast ChIP method61 as described.29 Chro-
matin was immunoprecipitated using 2 mg speciﬁc antibodies.
SYBR green qPCR assays were performed as described.29 Oligonucle-
otide primer sequences are provided in Table S7.
Bisulfite Sequencing
Bisulﬁte sequencing (BSS) was performed on genomic DNAs isolated
from lentiviral-infected 17Abic differentiated myocytes. DNA
methylation at the distal pathogenic D4Z4 repeat was analyzed using
the 4qA BSS assay as described23,24 or using primers amplifying exon
3 from 4qA (Table S7).
Statistics
Statistical analysis was performed using R62 with log2-transformed
gene expression or ChIP enrichment data. Levene’s test shows that
the assumption of homogeneity of variances is met. Pre-determined
contrast was made between knockout and the corresponding empty
vector within the framework of ANOVA using randomized
block design (patient as block for Figure 2, experiment as block for
Figures 3 and 4; n = 3–5). Fusion index (Figure S1) was ﬁrst
arcsine-transformed to homogenize the variance. Levene’s test shows
that the assumption of homogeneity of variances is met. ANOVA of
the randomized block design was performed followed by predeter-
mined contrasts.
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